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Abstract
Background
There is limited knowledge of the scale and impact of multimorbidity for patients who have
had an acute myocardial infarction (AMI). Therefore, this study aimed to determine the
extent to which multimorbidity is associated with long-term survival following AMI.
Methods and findings
This national observational study included 693,388 patients (median age 70.7 years,
452,896 [65.5%] male) from the Myocardial Ischaemia National Audit Project (England and
Wales) who were admitted with AMI between 1 January 2003 and 30 June 2013. There
were 412,809 (59.5%) patients with multimorbidity at the time of admission with AMI, i.e.,
having at least 1 of the following long-term health conditions: diabetes, chronic obstructive
pulmonary disease or asthma, heart failure, renal failure, cerebrovascular disease, periph-
eral vascular disease, or hypertension. Those with heart failure, renal failure, or cerebrovas-
cular disease had the worst outcomes (39.5 [95% CI 39.0–40.0], 38.2 [27.7–26.8], and 26.6
[25.2–26.4] deaths per 100 person-years, respectively). Latent class analysis revealed 3
multimorbidity phenotype clusters: (1) a high multimorbidity class, with concomitant heart
failure, peripheral vascular disease, and hypertension, (2) a medium multimorbidity class,
with peripheral vascular disease and hypertension, and (3) a low multimorbidity class.
Patients in class 1 were less likely to receive pharmacological therapies compared with
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class 2 and 3 patients (including aspirin, 83.8% versus 87.3% and 87.2%, respectively; β-
blockers, 74.0% versus 80.9% and 81.4%; and statins, 80.6% versus 85.9% and 85.2%).
Flexible parametric survival modelling indicated that patients in class 1 and class 2 had a
2.4-fold (95% CI 2.3–2.5) and 1.5-fold (95% CI 1.4–1.5) increased risk of death and a loss in
life expectancy of 2.89 and 1.52 years, respectively, compared with those in class 3 over the
8.4-year follow-up period. The study was limited to all-cause mortality due to the lack of
available cause-specific mortality data. However, we isolated the disease-specific associa-
tion with mortality by providing the loss in life expectancy following AMI according to multi-
morbidity phenotype cluster compared with the general age-, sex-, and year-matched
population.
Conclusions
Multimorbidity among patients with AMI was common, and conferred an accumulative
increased risk of death. Three multimorbidity phenotype clusters that were significantly
associated with loss in life expectancy were identified and should be a concomitant treat-
ment target to improve cardiovascular outcomes.
Trial registration
ClinicalTrials.gov NCT03037255.
Author summary
Why was this study done?
• Survival following a heart attack (acute myocardial infarction) has improved over recent
decades.
• The population is ageing, and there are more patients living longer with multiple long-
term health conditions (multimorbidity).
• Previous studies have looked at the associations between individual long-term health
conditions and survival following a heart attack, but little is known about patterns of
multiple conditions and how such multimorbidity patterns may be associated with
patients’ outcomes.
What did the researchers do and find?
• A total of 693,388 patients who had a heart attack between 2003 and 2013 across
England and Wales were included in the study.
• 59.5% of patients had at least 1 of the following long-term health conditions at the time
of their heart attack: diabetes, chronic obstructive pulmonary disease or asthma, heart
failure, renal failure, cerebrovascular disease (stroke), peripheral vascular disease, or
hypertension.
Multimorbidity and survival for patients with acute myocardial infarction
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• There were 3 common multimorbidity patient groups: (1) patients with high multimor-
bidity at the time of their heart attack, who tended to have heart failure as well as periph-
eral vascular disease and hypertension, (2) patients with medium multimorbidity at the
time of their heart attack, who tended to have peripheral vascular disease and hyperten-
sion, and (3) patients with few co-morbidities.
• Patients who had high and medium levels of multimorbidity had average reduced life
expectancies of 2.9 and 1.5 years, respectively, compared with patients who had few co-
morbidities.
What do these findings mean?
• This study shows that many patients with a heart attack have multimorbidity, and that
those with high and medium levels of multimorbidity are likely to experience a signifi-
cant reduction in years of life expectancy.
• Whilst this study included 7 conditions most commonly occurring in patients who have
a heart attack, there may be other conditions including dementia and cancer that
require investigation in this context.
• Future research should focus on developing treatment guidelines for the multimorbidity
patient groups identified to improve outcomes for heart attack patients with
multimorbidity.
Introduction
The increasing prevalence of long-term health conditions, and consequent growing prevalence
of multimorbidity (the presence of multiple co-morbidities), is a major global challenge facing
healthcare systems [1,2]. Presently, around two-thirds of patients with cardiovascular disease
are estimated to have at least 1 long-term health condition [3]. With improved survival rates
following acute myocardial infarction (AMI) as well as an ageing population [4–6], there are
more patients living longer with multimorbidity, which is associated with reduced quality of
life, increased healthcare burden, and increased mortality [3,7,8].
Although many prior studies have assessed the association between individual co-morbidi-
ties—including diabetes [9,10], chronic obstructive pulmonary disease (COPD) [11–15], and
heart failure [16]—and survival in patients with AMI, few have quantified the burden of multi-
morbidity—in particular how the complex patterns of multiple conditions simultaneously
associate with mortality. Where data do exist on multimorbidity clusters, studies are limited to
regional rather than national data and have relied on basic analytical techniques that consider
composite additive [17,18] or weighted [19–22] co-morbidity scores, or focus on all possible
combinations of conditions [18,23,24]. Moreover, previous data are mostly limited to short-
(30 days) and medium-term (1 year) outcomes, with the exception of the study by Di Angelan-
tonio et al. [24] (12.8 years of follow-up), even though such conditions are lifelong diseases
and, therefore, warrant investigation of outcomes over the longer term. More sophisticated
methods, such as latent class analysis, enable insights into multidimensional disease patterns
based on probabilistic modelling of specific conditions without the aforementioned limitations
Multimorbidity and survival for patients with acute myocardial infarction
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[25]. Furthermore, insights into the association of multimorbidity with survival following AMI
from latent class analysis may help define and target therapeutic strategies to specific groups of
patients in an attempt to reduce premature death [1,26,27].
Therefore, this study aimed to investigate which multimorbidity phenotype clusters exist
across a range of pre-existing long-term health conditions and study their association with
long-term survival for patients hospitalised with AMI. We hypothesise that the presence of
multimorbidity confers an increased long-term risk of death for patients with AMI. In
addressing this hypothesis, we provide a greater understanding of the clustering of pre-existing
conditions and their simultaneous burden on survival.
Methods
Ethical approval
The National Institute for Cardiovascular Outcomes Research, which includes the Myocardial
Ischaemia National Audit Project (MINAP) database (Ref: NIGB ECC 1-06(d)/2011), has sup-
port under section 251 of the National Health Service Act 2006 to use patient information for
medical research without informed consent. Further ethical approval, or patient consent, was
not required under current National Health Service research governance arrangements, and
all data analysed in the study were anonymised. This study is reported as per RECORD guide-
lines (S1 Checklist).
Data and patients
Data for this study were obtained from MINAP, representing all hospitals in a single health
system (the National Health Service in England and Wales). MINAP offers the opportunity to
undertake population-based observational studies of an array of multimorbid conditions and
their association with survival following AMI. Full details of MINAP have been published else-
where [28]. The analytical cohort (n = 693,388) was drawn from 693,633 patients with AMI
admitted to 1 of 247 hospitals between 1 January 2003 and 30 June 2013 (S1 Text; S1 Fig).
Patients were eligible for the study if they were aged 18 years or over; where multiple admis-
sions for AMI were recorded per person, only the first admission was included. We excluded
245 (0.04%) patients due to missing mortality data. Patients were defined as having multimor-
bidity if they had a history of 1 or more of the following conditions when admitted to hospital
with AMI: diabetes mellitus, COPD or asthma, chronic heart failure, chronic renal failure
(defined as creatinine chronically >200 μmol/l [>2.26 mg/dl]), cerebrovascular disease,
peripheral vascular disease, or hypertension (defined as a patient already receiving treatment
[drug, dietary, or lifestyle] for hypertension or with recorded blood pressure >140/90 mm Hg
on at least 2 occasions prior to admission).
Patient-level data included baseline ischaemic risk (calculated using the Global Registry
of Acute Coronary Events [GRACE] risk score parameters: age, cardiac arrest, electrocar-
diographic ST segment deviation, elevated cardiac enzymes, systolic blood pressure, heart rate
on admission to hospital, prescription of a loop diuretic [substituted for Killip class] and creat-
inine [29,30]), patient demographics (sex and index of multiple deprivation [31]), type of AMI
(ST-elevated myocardial infarction [STEMI] and non-ST-elevated myocardial infarction
[NSTEMI]), medical history (smoking status, family history of coronary heart disease, hyper-
tension, total cholesterol, previous AMI, angina, percutaneous coronary intervention, and cor-
onary artery bypass graft surgery), pharmacological therapies at the time of discharge from
hospital (aspirin, β-blockers, HMG-CoA reductase inhibitors [statins], ACE inhibitors/angio-
tensin receptor blockers, P2Y12 inhibitors, and aldosterone antagonists), revascularisation
strategy (thrombolysis or coronary intervention [percutaneous coronary intervention or
Multimorbidity and survival for patients with acute myocardial infarction
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coronary artery bypass graft surgery] or both), and all-cause mortality (through patient-level
linkage to the United Kingdom Office for National Statistics). Patients were followed up for
mortality status to a censoring date of 30 April 2011 for those diagnosed between 2003 and
2009, and a final censoring date of 31 December 2013 for those diagnosed from 2010 onwards.
This resulted in a maximum observed follow-up time of 8.4 years (median and interquartile
range: 2.3, 0.9–4.0 years), representing 1,872,468 person-years at risk.
Statistical analyses
While no formal analysis plan exists, all analytical methods described here were planned pro-
spectively prior to analyses. Where data-driven approaches were used for model selection, or
sensitivity analyses conducted as a result of peer review, this has been clearly indicated below.
Latent class analysis was performed to assimilate individual patient data for multiple long-
term health conditions into multimorbidity classes. The resultant classes represented probabi-
listic groups of patients with similar combinations of conditions, and as such depicted complex
patterns of higher order interactions between multiple conditions (S3 Text; S3 Fig; S4 Table).
The latent class analysis was based only on the probability distributions of the baseline long-
term health conditions and did not take outcomes into account. Latent class analysis was pre-
ferred over simpler techniques such as creating an additive score of long-term health condi-
tions, through which the granularity of specific combinations of conditions would be lost, or
analysing all possible combinations of conditions, which is subject to high false positive rates
(type I errors) and can lead to low study power.
Baseline characteristics were described according to each multimorbidity phenotype cluster
using numbers and percentages for categorical data and means and standard deviations and
medians and interquartile ranges for normally and non-normally distributed continuous vari-
ables, respectively. The differences in baseline characteristics between multimorbidity pheno-
type clusters were summarised using chi-squared tests, t tests, and Wilcoxon rank-sum tests
appropriate to the data type and distribution. Furthermore, differences in receipt of guideline-
recommended therapies were compared according to multimorbidity phenotype cluster.
Royston–Parmar flexible parametric survival models [32] based on all-cause mortality were
fitted to determine the association of multimorbidity phenotype clusters with long-term sur-
vival (8.4 years). In addition, the association of individual pre-existing conditions and the
accumulation of multimorbid conditions (grouped into 0, 1, and 2 or more conditions) with
long-term survival was assessed using the same flexible parametric survival models. Left ven-
tricular ejection fraction (LVEF; categorised as good,50%; moderate, 30%–49%; and poor,
<30%) and estimated glomerular filtration rate (eGFR; categorised as normal or mild
impairment,60 ml/min per 1.73 m2; moderate impairment, 30–59 ml/min per 1.73 m2; or
severe/very severe impairment, <30 ml/min per 1.73 m2) were used to model the association
of the severity of chronic heart failure and chronic renal failure, respectively, with survival.
The models were adjusted for known confounders based on clinical consideration and previ-
ous research [27,33] including baseline ischaemic risk, demographic variables, type of AMI,
medical history, revascularisation strategy, and pharmacological therapies at discharge as
defined earlier. We selected flexible parametric models a priori in favour of standard Cox
regression to allow for modelling of non-proportional hazards as well as extension to a relative
survival framework for calculation of loss in life expectancy (more details below). Further sen-
sitivity analyses were conducted following peer review in order to assess the impact of the
increase in recorded multimorbidity between 2003 and 2004 upon the results (S3 Table).
Finally, we estimated the loss of life expectancy in years compared with the age-, sex-, and
year-matched populace of the UK [34] that was due to multimorbidity phenotype cluster as
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well as according to individual and cumulative conditions. Mortality data for England and
Wales were obtained from Office for National Statistics life tables [35] (S4 Text).
Multiple imputation by chained equations was used to produce 10 imputed datasets to min-
imise potential bias due to missing data (S2 Text; S1 Table), using previously defined methods
for imputation of the MINAP data [36]. Pooled estimates and accompanying 95% confidence
intervals were generated according to Rubin’s rules [37]. The scale (proportional hazards, propor-
tional odds, or normal) and complexity (number of degrees of freedom) for flexible parametric
survival models were determined by minimising the Akaike information criterion and the Bayes-
ian information criterion for the complete case analysis as well as for each individual imputation.
According to good practice guidelines for multiple imputation, a sensitivity analysis comparing
the main imputed analysis with a complete case analysis was conducted (S2 Table; S2 Fig). All
tests were 2-sided, and statistical significance was considered as P< 0.05. Statistical analyses were
performed in Stata MP version 14 (http://www.stata.com/), R version 3.1.2 (https://cran.r-project.
org/), and Mplus version 7.3 (https://www.statmodel.com/).
Results
There were a total of 693,388 patients included (median age 70.7 years; 452,896 [65.5%] men)
and 1,872,468 person-years follow-up. There were 412,809 (59.5%) patients with AMI who
had at least 1 pre-existing co-morbid condition. The majority of these had 1 condition
(238,302, 57.7%), whereas 120,693 (29.2%) had 2, and 53,814 (13.0%) had 3 or more, up to a
maximum of 7 (63, 0.02%). The most prevalent conditions were hypertension (n = 302,388,
45.9%), diabetes mellitus (n = 122,228, 18.6%), and COPD or asthma (n = 89,211, 13.6%).
Whilst chronic renal failure, chronic heart failure, and peripheral vascular disease were the
least prevalent, patients with these conditions most frequently had additional conditions
(27,812 [89.6%], 28,445 [84.1%], and 23,201 [84.0%], respectively) (Fig 1).
Latent class analysis revealed 3 distinct groups of patients in terms of their multimorbidity
profile: class 1, a high multimorbidity cluster, with concomitant heart failure, peripheral vascu-
lar disease, and hypertension; class 2, a medium multimorbidity cluster, with peripheral vascu-
lar disease and hypertension; and class 3, with low levels of multimorbidity overall but with
peripheral vascular disease (Fig 2; S5 Table).
Patients in multimorbidity class 1 (high multimorbidity with concomitant heart failure,
peripheral vascular disease, and hypertension) tended to be older (median age 78.9 years; IQR
71.0–84.8) than those in multimorbidity class 2 (medium multimorbidity with concomitant
peripheral vascular disease and hypertension; median age 74.0 years; IQR 64.8–81.3) and mul-
timorbidity class 3 (low levels of multimorbidity overall but with peripheral vascular disease;
median age 68.5 years; IQR 57.5–79.0). Class 1 patients also tended to be female (40.5% versus
38.5% and 33.1%, respectively) and more often had NSTEMI (83.2%) than STEMI compared
with class 2 and 3 patients (71.6% and 57.6%, respectively). Furthermore, patients in class 1
were less likely to receive pharmacological therapies after accounting for eligibility compared
with class 2 and 3 patients (Table 1). Of note, there were more people in the high and medium
multimorbidity phenotype clusters (class 1 and 2) in the latest period of the study compared
with the earliest period (class 1: 9.0% in 2011–2013 versus 7.9% in 2003–2006; class 2: 16.6% in
2011–2013 versus 13.9% in 2003–2006). There was an associated 2.0% (95% CI 1.9%–2.3%)
increase in the number of conditions per year (Fig 1).
Outcomes
Unadjusted all-cause mortality was higher for those in class 1 than for those in classes 2 and 3
at 30 days (17.0% [95% CI 16.7%–17.4%] versus 10% [9.7%–10.1%] and 7.4% [7.3%–7.5%],
Multimorbidity and survival for patients with acute myocardial infarction
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respectively; P< 0.001), 1 year (39.8% [39.3%–40.2%] versus 21.4% [21.1%–21.6%] and 14.4%
[14.2%–14.5%]; P< 0.001), and 5 years (57.4% [57.0%–57.9%] versus 34.0% [33.6%–34.3%]
and 22.4% [22.3%–22.6%]; P< 0.001).
Those in the high multimorbidity cluster with chronic heart failure, peripheral vascular dis-
ease, and hypertension (class 1) had a 2.4-fold increased hazard of death compared with low-
multimorbidity patients (class 3) (hazard ratio [HR] 2.40; 95% CI 2.33–2.47) over the 8.4-year
follow-up period. Those who were in the medium multimorbidity cluster with peripheral vas-
cular disease and hypertension (class 2) had a 1.5-fold increased hazard compared with those
with low levels of multimorbidity (class 3) (HR 1.45; 95% CI 1.41–1.48) (Table 2).
For individual conditions, the worst outcomes were observed in patients with chronic heart
failure (8.4-year mortality rate 63.5%, 95% CI 63.0%–64.1%; adjusted HR 1.87, 95% CI 1.81–
1.93; median time to death 131.49 days, IQR 18.3–518.7; 39.5 deaths per 100 person years
[/100 py]), chronic renal failure (8.4-year mortality rate 57.2%, 95% CI 56.7%–57.8%; adjusted
HR 1.73, 95% CI 1.67–1.79; median time to death 116.9 days, IQR 18.3–449.3; 38.2 deaths/100
py), and cerebrovascular disease (8.4-year mortality rate 50.7%, 95% CI 50.3%–51.1%; adjusted
HR 1.77, 95% CI 1.72–1.82; median time to death 142.5 days, IQR 14.6–573.4; 26.6 deaths/100
py) (Fig 3; Table 2). There was a corresponding decline in prognosis with decreasing LVEF
(HR 1.27 [95% CI 1.10–1.47] and 1.91 [1.64–2.22] for moderate and poor LVEF, respectively,
Fig 1. Time trends and prevalence of multimorbid conditions for patients hospitalised with acute myocardial
infarction in England and Wales, 2003–2013. (A) Time trends. (B) Prevalence. COPD, chronic obstructive
pulmonary disease.
https://doi.org/10.1371/journal.pmed.1002501.g001
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compared with good LVEF) and eGFR (HR 1.47 [1.25–1.74] and 2.01 [1.71–2.37] for moderate
and severe/very severe impairment, respectively, compared with mild impairment or normal
eGFR). Moreover, after adjustment for confounders, the accumulation of multimorbid condi-
tions for patients with AMI was significantly associated with worse survival (HR 1.32 [95% CI
1.29–1.34] for 1 condition and HR 1.98 [1.94–2.03] for 2 or more conditions versus no multi-
morbidity; P-value for trend < 0.001).
The association between individual long-term health conditions and survival translated
into a significant loss in life expectancy, such that those with chronic heart failure, chronic
renal failure, and peripheral vascular disease had a loss in life expectancy of 2.91 (95% CI 2.58–
3.25), 2.78 (95% CI 2.47–3.10), and 2.14 (95% CI 1.86–2.42) years, respectively, compared to
those without long-term conditions (S7 Table). Moreover, multimorbidity was also associated
with significant loss in life expectancy, such that those in class 1 had a loss in life expectancy of
2.89 years (95% CI 2.59–3.19), and those in class 2 a loss in life expectancy of 1.52 years (95%
CI 1.33–1.71), compared with class 3 patients.
Fig 2. Probabilistic distribution of multimorbid conditions within each multimorbidity phenotype cluster. S5 Table provides the full probabilistic latent
class structure. The observed proportions of patients with and without each condition per class indicate that class 1 characterises patients with high
multimorbidity, especially including chronic heart failure, peripheral vascular disease, and hypertension; class 2 characterises patients with medium
multimorbidity, especially including peripheral vascular disease and hypertension; and class 3 characterises patients with low multimorbidity but with peripheral
vascular disease. COPD, chronic obstructive pulmonary disease.
https://doi.org/10.1371/journal.pmed.1002501.g002
Multimorbidity and survival for patients with acute myocardial infarction
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002501 March 6, 2018 8 / 18
Table 1. Baseline characteristics stratified according to multimorbidity phenotype cluster at the time of acute myocardial infarction hospitalisation, 2003–2013
(prior to multiple imputation for missing data).
Variable Measure Total cohort, N =
693,388
Multimorbidity phenotype cluster1 P-value2 Missing (%)3
Class 1
N = 47,839
Class 2
N = 87,009
Class 3
N = 433,215
Total
cohort
Class 1 Class 2 Class 3
Age (years)4 Median
(IQR)
70.7 (59.4–80.1) 78.9 (71–84.8) 74 (64.8–
81.3)
68.5 (57.5–
79.0)
<0.001 0.1 0.1 0.1 0.1
Sex (male)5 N (%) 452,896 (65.5) 28,613 (59.9) 53,412 (61.5) 288,948
(66.9)
<0.001 0.3 0.1 0.2 0.2
Year of admission6 <0.001 0 0 0 0
2003–2006 N (%) 244,499 (35.3) 14,040 (7.9) 24,764 (13.9) 139,769
(78.3)
2007–2010 N (%) 274,085 (39.5) 19,748 (8.5) 36,458 (15.6) 177,605
(76.0)
2011–2013 N (%) 174,804 (25.2) 14,051 (9.0) 25,787 (16.6) 115,841
(74.4)
Index of multiple deprivation5 Median
(IQR)
18.3 (10.6 to 31.8) 19.4 (11.3–
33.5)
19.5 (11.2–
33.7)
17.7 (10.3–
30.6)
<0.001 8.2 7.9 7.5 8.0
GRACE risk score7 <0.001 56.0 45.6 46.6 50.5
<70 N (%) 21,686 (7.1) 258 (1.0) 1,707 (3.7) 18,606 (8.7)
70–87 N (%) 33,539 (11.0) 576 (2.2) 3,539 (7.6) 27,785 (13.0)
88 N (%) 249,892 (81.9) 25,187 (96.8) 41,231 (88.7) 167,975
(78.4)
Index AMI STEMI(versus
NSTEMI)
N (%) 274,220 (39.5) 8,019 (16.8) 24,721 (28.4) 183,601
(42.4)
<0.001 0 0 0 0
SBP (mm Hg)4 Mean (SD) 139.2 (29) 137.1 (30.6) 142.2 (29.9) 138.9 (28.4) <0.001 19.3 10.3 10.5 11.3
Heart rate (beat/min)4 Mean (SD) 81.9 (23.2) 88.3 (24.6) 84.4 (23.2) 80.6 (22.6) <0.001 19 10.1 10.3 10.9
Total cholesterol (mmol/l)8 Median
(IQR)
5.0 (1.4) 4.2 (1.4) 4.4 (1.4) 5.2 (1.4) <0.001 35.7 48.6 39.0 32.0
Creatinine (μmol/l) Median
(IQR)
91.0 (76.0–112.0) 131.0 (98.0–
188.0)
97.0 (79.0–
124.0)
88.0 (74.0–
105.0)
<0.001 44.5 35.5 35.4 39.1
Medical history5
Current or ex-smoker N (%) 390,956 (62.2) 26,406 (60.6) 48,858 (59.9) 262,649
(64.0)
<0.001 9.4 8.9 6.2 5.2
Family history of coronary heart
disease
N (%) 140,388 (32.7) 6,358 (21.1) 18,338 (30.0) 104,220
(33.8)
<0.001 38.2 37.0 29.6 28.8
Previous AMI N (%) 136,482 (21.9) 20,620 (43.5) 25,791 (29.8) 74,360 (17.2) <0.001 10.1 0.9 0.5 0.3
Previous angina N (%) 169,454 (27.5) 23,547 (49.7) 33,206 (38.4) 94,389 (21.9) <0.001 11.2 1.0 0.7 0.4
Admission treatment5
Revascularisation9 N (%) 227,275 (42.1) 5,238 (14.8) 18,149 (26.9) 145,951
(42.7)
<0.001 22.2 26.2 22.5 21.1
Loop diuretic N (%) 155,674 (28.1) 27,894 (62.9) 29,265 (36.8) 85,848 (22.0) <0.001 20.1 7.3 8.7 10.0
Discharge medication5
Aspirin N (%) 510,387 (85.7) 31,780 (83.8) 6,384 (87.3) 329,292
(87.2)
<0.001 9.5 20.7 15.9 12.8
β-blocker N (%) 427,191 (79.1) 23,443 (74.0) 54,013 (80.9) 280,719
(81.4)
<0.001 10.3 33.8 23.3 20.4
Statin N (%) 503,686 (83.4) 31,718 (80.6) 64,379 (85.9) 324,934
(85.2)
<0.001 10.1 17.7 13.9 11.9
ACEi or ARB N (%) 442,954 (77.5) 25,175 (74.7) 56,717 (80.6) 289,225
(79.4)
<0.001 10.7 29.5 19.1 15.9
P2Y12 inhibitor N (%) 217,539 (94.4) 14,854 (94.9) 30,730 (95.0) 147,771
(94.8)
0.264 56.2 67.3 62.8 64.0
Aldosterone antagonist N (%) 17,035 (10.3) 2,826 (21.8) 2,655 (11.1) 9,825 (8.8) <0.001 60.0 72.9 72.6 74.1
(Continued)
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Discussion
In this nationwide study of patients hospitalised with AMI, almost two-thirds had multimor-
bidity, most commonly with hypertension and diabetes mellitus. Those with 1 long-term
health condition in addition to AMI were 32% more likely to die over the 8.4-year follow-up
period, whereas those with 2 or more long-term health conditions were twice as likely to die,
compared with those without multimorbidity. Each condition was associated with a unique
and significant loss of life expectancy, which was greatest for those with chronic heart failure.
Using latent class analysis, we identified 3 patient groups based on their probability of long-
term health conditions that had distinct survival trajectories and may be considered as novel
post-AMI survival phenotypes.
Global population demographics have changed such that nowadays patients with AMI are
older and have more co-morbidities [38,39]. This and the fact that mortality rates from AMI
have declined have created a new cohort of patients with multimorbidity who are now living
with the aftermath of AMI [27]. In the United States, this amounts to over 85 million people
(and 7 million in the United Kingdom) living with cardiovascular disease, of whom the major-
ity are elderly or have co-existent long-term health conditions [40,41]. The resultant healthcare
utilisation and associated direct costs are high and escalate according to multimorbidity
[42,43]. A key international healthcare priority, therefore, is the reduction in multimorbidity
and improvement in disease-free survival. To date, however, studies reporting multimorbidity
have either focused on individual conditions [9–11,13,16] or have been largely limited to re-
gional data with short-term outcomes [18,23]. Our study clearly depicts, in a modern health-
care system, the considerable burden of multimorbidity among patients with AMI and,
importantly, identified clear patient classes for clusters of such conditions, such that multidis-
ciplinary interventions may be targeted towards those in greatest need.
Table 1. (Continued)
Variable Measure Total cohort, N =
693,388
Multimorbidity phenotype cluster1 P-value2 Missing (%)3
Class 1
N = 47,839
Class 2
N = 87,009
Class 3
N = 433,215
Total
cohort
Class 1 Class 2 Class 3
Mortality (unadjusted)
30 days N (%) 62,950 (9.1) 8,139 (17.0) 8,656 (10.0) 32,002 (7.4) <0.001 0 0 0 0
1 year N (%) 102,254 (14.8) 19,025 (39.8) 18,600 (21.4) 62,151 (14.4) <0.001 0 0 0 0
5 years N (%) 204,667 (29.5) 27,471 (57.4) 29,537 (34.0) 97,161 (22.4) <0.001 0 0 0 0
1Class 1 characterises patients with high multimorbidity, especially with concomitant chronic heart failure, peripheral vascular disease, and hypertension. Class 2
characterises patients with medium multimorbidity, especially peripheral vascular disease and hypertension. Class 3 characterises patients with low multimorbidity but
with peripheral vascular disease.
2P-value for difference between classes.
3S6 Table contains patient characteristics for those with missing latent class data (prior to multiple imputation for missing data).
4Values are means and standard deviations, and P-values are derived from t tests.
5Values are numbers and percentages, and P-values are derived from chi-squared tests.
6Column percentages shown to highlight temporal trend.
7Given international guidelines, Global Registry of Acute Coronary Events (GRACE) risk score was categorised into lowest (<70), low (70 to 87), and intermediate-to-
high risk (88).
8Values are medians and interquartile ranges, and P-values are derived from Wilcoxon rank-sum tests.
9Thrombolysis or coronary intervention (percutaneous coronary intervention or coronary artery bypass graft surgery) or both.
ACEi, angiotensin-converting enzyme inhibitor; AMI, acute myocardial infarction; ARB, angiotensin receptor blocker; NSTEMI, non-ST-elevated myocardial
infarction; SBP, systolic blood pressure; STEMI, ST-elevated myocardial infarction.
https://doi.org/10.1371/journal.pmed.1002501.t001
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Table 2. Unadjusted and adjusted HRs for long-term survival according to multimorbidity class or health condition obtained from flexible parametric survival
models after multiple imputation (5 degrees of freedom, odds scale).
Multimorbidity or long-term health
condition
Deaths per 100 person-years
(95% CI)
Median time to death in
days (IQR)
Unadjusted HR (95% CI) or
P-value
Adjusted HR (95% CI)1 or
P-value
Multimorbidity phenotype cluster2 P< 0.001 P< 0.001
Class 1 36.7 (36.6–37.2) 138.9 (21.0–499.7) 4.20 (4.13–4.28) 2.40 (2.33–2.47)
Class 2 15.5 (15.4–15.7) 197.9 (27.4–657.5) 1.80 (1.78–1.83) 1.45 (1.41–1.48)
Class 3 8.6 (8.5–8.6) 176.9 (15.0–696.5) 1 (ref) 1 (ref)
Diabetes mellitus P< 0.001 P< 0.001
Yes 16.6 (16.5–16.8) 189.9 (21.9–657.5) 1.68 (1.65–1.70) 1.21 (1.19–1.24)
No 9.9 (9.8–9.9) 175.9 (15.0–705.5) 1 (ref) 1 (ref)
COPD or asthma P< 0.001 P< 0.001
Yes 17.2 (17.0–17.4) 186.3 (18.3–657.5) 1.68 (1.66–1.71) 1.17 (1.14–1.19)
No 10.2 (10.1–10.2) 176.9 (15.0–701.5) 1 (ref) 1 (ref)
Chronic heart failure P< 0.001 P< 0.001
Yes 39.5 (39.0–40.0) 131.5 (18.3–518.7) 3.94 (3.86–4.03) 1.87 (1.81–1.93)
No 10.0 (9.9–10.0) 189.9 (16.0–719.5) 1.86 (1.70–2.04) 1.91 (1.64–2.22)
LVEF P< 0.001 P< 0.001
Moderate (30%–49%) 33.0 (31.5–34.6) 159.9 (42.9–484.7) 1.21 (1.10–1.33) 1.27 (1.10–1.47)
Poor (<30%) 45.1 (43.1–47.0) 94.9 (19.0–356.8) 1.86 (1.70–2.04) 1.91 (1.64–2.22)
Good (50%) 28.8 (27.1–30.5) 190.9 (54.0–514.6) 1 (ref) 1 (ref)
Chronic renal failure P< 0.001 P< 0.001
Yes 38.2 (37.7–38.8) 116.9 (18.3–449.3) 3.41 (3.34–3.48) 1.73 (1.67–1.79)
No 10.2 (10.1–10.2) 190.9 (16.0–725.5) 1 (ref) 1 (ref)
eGFR (ml/min per 1.73 m2) P< 0.001 P< 0.001
Moderate impairment (30–59) 33.5 (32.5–34.5) 135.9 (23.0–477.7) 1.70 (1.51–1.92) 1.47 (1.25–1.74)
Severe/very severe impairment (<30) 54.4 (53.0–55.8) 95.9 (13.0–402.7) 2.72 (2.41–3.08) 2.01 (1.71–2.37)
Normal or mild impairment (60) 20.6 (19.1–22.1) 154.9 (25.0–506.7) 1 (ref) 1 (ref)
Cerebrovascular disease P< 0.001 P< 0.001
Yes 26.6 (25.2–26.9) 142.5 (14.6–573.4) 2.71 (2.66–2.75) 1.77 (1.72–1.82)
No 10.0 (9.9–10.0) 186.9 (16.0–714.5) 1 (ref) 1 (ref)
Peripheral vascular disease P< 0.001 P< 0.001
Yes 22.7 (22.3–23.1) 175.3 (18.3–628.2) 2.15 (2.10–2.20) 1.41 (1.36–1.46)
No 10.6 (10.5–10.6) 179.9 (16.0–697.5) 1 (ref) 1 (ref)
Hypertension P< 0.001 P< 0.001
Yes 12.5 (12.4–12.6) 194.0 (19.0–698.0) 1.28 (1.27–1.30) 1.03 (1.02–1.06)
No 9.6 (9.5–9.7) 163.0 (14.0–688.0) 1 (ref) 1 (ref)
Cumulative number of conditions P< 0.001 P< 0.001
1 10.7 (10.6–10.7) 181.8 (16.0–698.5) 1.69 (1.67–1.72) 1.32 (1.29–1.34)
2 or more 20.0 (19.9–20.2) 173.9 (20.8–603.6) 3.29 (3.25–3.34) 1.98 (1.94–2.03)
None 6.4 (6.4–6.5) 179.9 (12.0–783.5) 1 (ref) 1 (ref)
1Adjusted for sex, year of admission, index of multiple deprivation (continuous), Global Registry of Acute Coronary Events (GRACE) risk score (categorised into lowest
[<70], low [70 to 87], and intermediate-to-high risk [88]), type of AMI (ST-elevated myocardial infarction versus non-ST-elevated myocardial infarction), smoking
status, family history of coronary heart disease, history of hypertension, previous AMI, previous percutaneous coronary intervention, serum cholesterol (continuous),
revascularisation (thrombolysis or coronary intervention [percutaneous coronary intervention or coronary artery bypass graft surgery] or both), and discharge
medications (aspirin, β-blockers, ACE inhibitors/angiotensin receptor blockers, statins, P2Y12 inhibitors, and aldosterone antagonists).
2Class 1 characterises patients with high multimorbidity, especially with concomitant chronic heart failure, peripheral vascular disease, and hypertension, Class 2
characterises patients with medium levels of multimorbidity, especially peripheral vascular disease and hypertension. Class 3 characterises patients with low levels of
multimorbidity but with peripheral vascular disease.
AMI, acute myocardial infarction; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HR, hazard ratio; LVEF, left ventricular
ejection fraction.
https://doi.org/10.1371/journal.pmed.1002501.t002
Multimorbidity and survival for patients with acute myocardial infarction
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002501 March 6, 2018 11 / 18
We noted that patients with AMI who also had a history of chronic heart failure, peripheral
vascular disease, and hypertension had the worst prognosis. Such patients lived, on average,
for about 4.5 months after hospitalisation and, after standardisation to population mortality
rates, were estimated to have lost up to 5.5 years of life. Others have reported the detrimental
effects of heart failure, yet the paucity of evidence for heart failure and multimorbidity is
acknowledged [44]. Few have quantified the association of heart failure with prognosis after
AMI [16,45], and, to our knowledge, none have identified the poor prognosis after AMI in
combination with other co-morbidities within a national and contemporary dataset. Patients
with cerebrovascular disease and chronic renal failure also had very poor outcomes, living on
average 3 to 4 months after hospitalisation with AMI. Moreover, there was a cumulative deficit
in survival among patients with more than 1 long-term health condition, such that those with
2 or more conditions in addition to AMI were twice as likely to die as those with none of the
pre-existing conditions, and this level of multimorbidity was associated with between 1.9 and
2.6 expected years of life lost.
The identification of specific survival trajectories for phenotype clusters of multimorbidity
has potentially important repercussions. This is because the proportion of patients with only 1
condition was lower than that for multiple conditions, and multimorbidity was more prevalent
in the later years of the study. Future healthcare demands are therefore likely to arise from
post-AMI patients with multimorbidity. To account for all possible multimorbid disease com-
binations and to investigate whether unique multimorbid phenotypes existed, we employed
latent class analysis. This data-driven technique identified 3 significantly different disease-
Fig 3. Long-term survival according to multimorbidity phenotype. Unadjusted Kaplan–Meier curves according to individual conditions (A),
cumulative number of conditions (B), and multimorbidity phenotype cluster of multimorbid conditions (C).
https://doi.org/10.1371/journal.pmed.1002501.g003
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determined prognostic groups (so called ‘computational phenotypes’) [46]. Understanding the
components of these classes of disease survivorship may help refine approaches to healthcare
and stimulate the development of innovative health technologies aimed at improving clinical
outcomes.
Although we found that patients with multimorbidity were less likely to receive guideline-
indicated care, after adjustment for this, as well as patient demographics, these patients contin-
ued to have a significantly poorer prognosis. This suggests that even though outcomes could
be improved to an extent through the greater provision of evidence-based in-hospital care,
additional and/or novel interventions are warranted in this vulnerable population. For exam-
ple, for heart failure and AMI, the design of new pharmacotherapies or greater use of commu-
nity-based interventions such as homecare and follow-up visits may be important. It is worth
noting that medical research designs such as randomised trials are optimised to focus on single
diseases and single disease pathways: our findings suggest the importance of developing appro-
priate research designs for people with multiple diseases.
Our analyses are likely to have underestimated the association of multimorbidity with sur-
vival following AMI. This is because (1) some long-term health conditions may have been
under-recorded in MINAP and (2) we did not have information about other diseases such as
chronic arthritis, mental illness, dementia, obesity, cancer, and inflammatory bowel disease.
However, in the calculation of years of life lost, we standardised by age, sex, and year to popu-
lation mortality rates to ascertain relative survival. This technique allowed estimation of the
association of index AMI with survival. On the other hand, it is possible that some patients
may have had end-stage diseases, multiple intractable conditions, or frailty, whereby it may
not have been appropriate to escalate care [47], and end-of-life decisions may have been
commenced.
Strengths and limitations
To our knowledge, MINAP is the largest nationwide single healthcare system database cover-
ing a prospective cohort of acute coronary syndromes. MINAP is designed to be representative
of the management of acute coronary syndromes in a clinical setting, and our previous work
has shown results consistent with those produced by randomised clinical trial data replicated
in a real-world clinical setting [27]. Previous studies assessing a number of conditions have
tended to rely on basic analytical techniques that either consider conditions independently or
investigate all possible combinations of conditions [18,23]. Such techniques result in high rates
of false positives (type I errors) and suffer from low statistical power. This study used latent
class analysis to provide further insight into multidimensional disease patterns using a data-
driven, probabilistic modelling approach. This allowed us to model the complex disease inter-
actions of multiple conditions and their association with survival in a more sophisticated man-
ner and without the aforementioned limitations. Despite these strengths, there were other
study limitations. First, the study was reliant upon the accurate recording of data, and MINAP
does not have 100% case ascertainment. Second, missing data, in particular missing data for
each of the multimorbid conditions, could have biased the estimates. However, a thorough
imputation strategy, including for multimorbid conditions, was implemented to minimise bias
following a previous comprehensive study of the nature of missing data within MINAP [36].
Third, the study was limited to all-cause mortality due to the lack of available cause-specific
mortality data. However, it has been shown that cause-specific mortality data may not always
be reliable for cardiovascular-related causes of death [48]. Fourth, the study included historical
data ranging from 2003 to 2013, which may therefore underestimate the most recent survival
rates, due to improved treatments over time. Moreover, there was an apparent increase in the
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number of multimorbid conditions from 2003 to 2004, which may be a result of improved
recording following the introduction of the quality outcomes framework in 2004, which incen-
tivised general practitioners to screen for and identify co-morbid conditions, or a result of
improved case ascertainment in this time period for patients who had NSTEMI, amongst
whom multimorbidity tends to be more common. Fifth, the observational nature of the study
means that we cannot demonstrate causation, though adjustment was made for confounders
based on a rich set of available information in the study dataset and informed by external
information from other studies.
Conclusions
Among patients hospitalised with AMI, pre-existing multimorbid conditions were common
and significantly associated with reduced survival. In particular, the presence of chronic heart
failure, cerebrovascular disease, and chronic renal failure independently conferred the greatest
risk of mortality and highest expected years of life lost. Three novel computational phenotypes
of survivorship according to multimorbidity were identified, which may direct future research
into the development of new pharmacotherapies and health service interventions for those in
greatest need. Addressing multimorbidity among patients hospitalised with AMI is a necessary
step in the international effort to reduce the burden of cardiovascular disease.
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